Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

Tribune News Service

‘Historic moment’: Drug slows cognitive decline in Alzheimer’s

It's being widely reported that an experimental drug has slowed the cognitive decline and brain damage in Alzheimer's patients.

The New Daily

Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review

The major indexes fell, with the S&P 500 breaking below bear market lows. Biogen soared on an Alzheimer's drug while Nike dived.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

9 Stocks Turned $10,000 Into $130,465 In 9 Months

It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it.

Investors Business Daily

5 bits of good news you might have missed this week - including Alzheimer's breakthrough

The news has been pretty bleak lately and it's been hard to keep up with all the sombre events that have been going on, so you may have missed a few stories that could make you a bit more hopeful for the future

Daily Mirror

Market Wrap: Volatility continues with pound’s flash-crash and a bearish US dollar

Volatility expected to remain heightened (in ‘both directions’) until the Fed manages to get inflation back under control.

The New Daily

Another prospect for an Alzheimer's drug renews cost concerns

But positive clinical trial results also renew the hopes of millions of seniors.

Axios

Read news from The Economist, FT, and more,
with one subscription

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

Benzinga

Netflix, Biogen And Other Big Gainers From Wednesday

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Benzinga

Dow Jones Futures Fall As Treasury Yields Rebound; Eli Lilly Leads 7 Bullish Stocks

Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.

Investors Business Daily

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

Benzinga

Dow Jones Jumps As Yields Plunge; This New Cathie Wood Buy Rockets; Bitcoin Rallies, Coinbase Jumps

The Dow Jones powered higher. A Cathie Wood buy was surging as Biogen exploded. Coinbase stock jumped as Bitcoin rose. Apple stock dived.

Investors Business Daily

What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data

Going back to at least December 2014, Biogen Inc (NASDAQ: BIIB) has been diligently working on drugs to cure Alzheimer's disease. Both the negative and positive data revealed over the years have instigated wild price gyrations in the issue.

Benzinga

Nasdaq Surges Over 150 Points; Gold Rises 2%

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Wednesday.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Biogen Stock Clings to Key Level After Explosive Rally

Biogen stock is up almost 40% on Wednesday but is barely holding above a key level. Let's look at the chart.

Investors Business Daily

Stock Market Gains, Led By Netflix, Oil, Biotech; Trade Deficit Drops

The stock market gained Wednesday as the trade deficit decreased. Netflix was one of the leading gainers.

Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session

Gainers

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Dow Jumps 300 Points; Crude Oil Rises Sharply

U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Wednesday.

Investors Business Daily

Stock Market Gains Strengthen As Yield Backs Away From 4%; This Biotech Soars 35%

The stock market strengthened in the first 30 minutes of trading. Biotechs rallied on news of positive trials.

AFP

Experts encouraged by Alzheimer drug preliminary data

Washington (AFP) - Experts on Wednesday said they were encouraged after preliminary data for a new Alzheimer's drug showed it slowed cognitive decline, the first medicine to accomplish this goal.

Benzinga

US Stocks Mixed; Wholesale Inventories Increase 1.3% In August

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 20 points on Wednesday.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

Upgrades

The Street

Is This the First Alzheimer's Drug to Actually Work?

Biogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study.

Investors Business Daily

Biogen Explodes Higher After Potential Mega Blockbuster Alzheimer's Drug Succeeds

Biogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.